Bausch + Lomb Launches Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes

New Preservative-Free and pH-Balanced Products Formulated for Irritated, Dry Eyes

Now Rolling out to Major U.S. Retailers

- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health"), today announced the U.S. launch of Biotrue ® Hydration Boost Lubricant Eye Drops and Biotrue ® Micellar Eyelid Cleansing Wipes. Both products are preservative-free and uniquely formulated with naturally inspired ingredients to relieve symptoms associated with irritated, dry eyes.

"One of the major culprits of dry eyes, which is one of the most common eye conditions in the United States 1 , is our increasing usage of digital devices. We developed Biotrue ® Hydration Boost Lubricant Eye Drops and Biotrue ® Micellar Eyelid Cleansing Wipes to provide instant moisture to help relieve dry, digital-device-weary eyes," said Joe Gordon , U.S. president, Bausch + Lomb. "Inspired by the biology of the eye, both products are free of preservatives and are pH-balanced."

Biotrue ® Hydration Boost Lubricant Eye Drops, which can be used while wearing soft contact lenses,* provide instant moisture and relief for irritated, dry eyes. These eye drops are pH-balanced to match healthy tears with ingredients that include an electrolyte, a component of natural, healthy tears, an antioxidant, to protect against free radicals, and hyaluronan (HA) 2 , a moisturizer found naturally in tears.

For some patients, eyelid buildup can be associated with irritated, dry eyes. Bausch + Lomb developed Biotrue ® Micellar Eyelid Cleansing Wipes to gently cleanse and hydrate the eyelid area to help eyes feel more comfortable. Similar to the Biotrue ® Hydration Boost Lubricant Eye Drops, the cleansing wipes are formulated with ingredients that include HA and an electrolyte as well as a micellar cleanser comprised of a naturally derived surfactant for gentle cleansing and aloe, licorice and dandelion root extract, which are naturally soothing.

"Many of my patients report having tired and irritated eyes at the end of the day, which is typically the result of prolonged digital device usage that can lead to eye dryness," said Jennifer Tsai , O.D., and founder, Line of Sight, New York . "The availability of Biotrue ® Hydration Boost Lubricant Eye Drops and Biotrue ® Micellar Eyelid Cleansing Wipes offers two convenient, over-the-counter options that I look forward to offering my patients to help relieve the symptoms of their dry, digitally irritated eyes."

Biotrue ® Hydration Boost Lubricant Eye Drops and Biotrue ® Micellar Eyelid Cleansing Wipes will be available for purchase in the eye care aisle or online at most national retailers, including Walgreens, CVS, Walmart, Target, Rite Aid and Amazon. Both will have a manufacturer's suggested retail price as low as $11.99 .

For more information on the Biotrue ® family of products, visit www.biotrue.com .

About Bausch + Lomb
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in approximately 100 countries. For more information, visit www.bausch.com .

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn .

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

References
1. Multi-sponsor Surveys, Inc., The 2017 Gallup Study of Dry Eye Sufferers.
2. HA is sourced from a large-scale natural fermentation process.

*Based on standardized testing of soft contact lenses. Not meant to lubricate or rewet lenses.

®/TM are trademarks of Bausch & Lomb Incorporated or its affiliates.
Any other product/brand names and/or logos are trademarks of the respective owners.
© 2021 Bausch & Lomb Incorporated or its affiliates.
BTW.0026.USA.21

Bausch Health Investor Contact:

Bausch Health Media Contact:

Arthur Shannon

Lainie Keller

arthur.shannon@bauschhealth.com

lainie.keller@bauschhealth.com

(514) 865-3855

(908) 927-1198

(877) 281-6642 (toll free)


Biotrue® Hydration Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes

(PRNewsfoto/Bausch Health Companies)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/bausch--lomb-launches-biotrue-hydration-boost-lubricant-eye-drops-and-biotrue-micellar-eyelid-cleansing-wipes-301331203.html

SOURCE Bausch Health Companies Inc.

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Bausch Health Companies Inc.

Bausch Health Companies Inc.

Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.

Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in Bernstein's 41st Strategic Decisions Conference on Thursday, May 29, 2025 .

Geoff Martha , Medtronic chairman and chief executive officer, will make a formal presentation beginning at 11:00 a.m. EDT ( 10:00 a.m. CDT ). Immediately following the presentation, Martha will be joined by Thierry Piéton, Medtronic executive vice president and chief financial officer, to answer questions about the company.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Medtronic announces intent to separate Diabetes business

Medtronic announces intent to separate Diabetes business

Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies

Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

  • FDA Breakthrough Device Designation Awarded to AVIM Therapy
  • FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2025, and provided a business update highlighting continued regulatory momentum, disciplined operational execution, and a strengthening clinical development pipeline.

Q1 2025 Highlights:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2025 on Wednesday, May 21, 2025 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's fourth quarter and full fiscal year 2025, which ended on Friday, April 25, 2025 .

Medtronic will host a video webcast at 7:00 a.m. CDT on May 21, 2025 , to discuss results for its fourth quarter and full fiscal year 2025. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

Star Jones , award winning television personality & women's heart health advocate,   helps kick off heart health conversations this Mother's Day with the Medtronic 'Letter to My Mother' campaign

A new Medtronic-sponsored survey of women ages 30-50 reveals a significant gap in awareness and discussion around heart health among women and their mother-figures. Despite cardiovascular disease being the #1 killer of women in the U.S. many women are still unaware of the risk and the importance of heart health.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×